Alpha-1 Antitrypsin Deficiency Treatment Market By End-use Industry Analysis and Opportunity Assessment 2019 to 2023

 Global Alpha-1 Antitrypsin Deficiency Treatment Market Research Report: By Drugs (Alpha-1 Proteinase Inhibitor,  Bronchodilators, Steroids, Others), By Route of Administration (Oral, Intravenous, Inhalation, Others) and By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Stores) – Forecast to 2025

Global Alpha-1 Antitrypsin Deficiency Treatment Market.

Market Forecast

Registering a CAGR of 10.50%, the Global Alpha-1 Antitrypsin Deficiency Treatment Market is expected to grow from USD 1,464.1 Million in 2018 to USD 2,914.7 Million by 2025.

Avail a Free Sample@ https://www.marketresearchfuture.com/sample_request/8319 

As of July 2019, 3.4 million people are affected by alpha-1 antitrypsin deficiency worldwide. The disorder is found to affect populations in all the regions of the world.

The market is dominated by numerous established players. The key players are involved in product launches, strategic collaborations, and awareness programs to strengthen their market positions. For instance, in November 2018, Grifols S. A. launched the AlfaCare therapy program for training and counseling of patients diagnosed with alpha-1 antitrypsin deficiency.

Market Influencer

The prevalence of alpha-1 antitrypsin deficiency (AATD) is increasing, which is directly responsible for the growth of the global alpha-1 antitrypsin deficiency treatment market. Strategic initiatives, mergers & acquisitions, partnerships, agreements, product launches, government approvals, and expansion of manufacturing facilities by major competitors are expected to further boost market growth during the forecast period.

Segmentation

By Drugs:

  • Alpha-1 Proteinase Inhibitor: The segment is expected to hold the largest market share as it is the only treatment for AATD, which protects the patient from more lung damage.
  • Bronchodilators: These are used for the treatment of respiratory disorders associated with AATD.
  • Steroids: These are used specifically for the treatment of chronic obstructive pulmonary disease, which affects the patient along with AATD.
  • Others: Other treatment options include antibiotics for infections and jaundice associated with AATD and oxygen therapy.

By Route of Administration:

  • Oral: The segment is expected to hold the largest market share.
  • Intravenous: The segment is expected to grow at the fastest CAGR.
  • Inhalation: This route of administration is used specifically for the administration of corticosteroids for treating breathing disorders.
  • Others: Subcutaneous and intramuscular routes of administration.

By Distribution Channel:

  • Hospital Pharmacy: The rise in the number of hospitals is likely to be responsible for the largest market size.
  • Retail Pharmacy: These fulfill the requirement of drugs that are needed for treatment at home.
  • Online Stores: The fastest-growing segment owing to increase in number of online pharmacies.

Browse Complete Report @ https://www.marketresearchfuture.com/reports/alpha-1-antitrypsin-deficiency-treatment-market-8319 

Key Players

  • Kamada Pharmaceuticals (Israel)
  • CSL Behring LLC (US)
  • Grifols, S.A. (Spain)
  • Takeda Pharmaceutical Company Limited (Japan)
  • GlaxoSmithKline plc (UK)
  • Boehringer Ingelheim GmbH (Germany)
  • AstraZeneca (UK)
  • Vectura Group plc (UK)
  • Pfizer Inc. (US)
  • Mylan Inc. (US)

Comments

Popular posts from this blog

Global Storage Tanks Market Sale Area and Revenue Analysis, Comprehensive Study Covid-19 Impact Analysis till 2026

Aluminum Cladding Panel Market Top Manufacturers Growth Insights and Future Outlook by IDA

Hydrogen Fluoride Market Rising Trends, Technology Advancements and In-depth Research Future Analysis